Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.
Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.
Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.
Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.
Astria Therapeutics (NASDAQ:ATXS) has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The company awarded options to purchase 43,650 shares of common stock at an exercise price of $5.40 per share, matching the closing price on April 1, 2025.
The options will vest over a four-year period, with 25% vesting on the first employment anniversary and the remaining shares vesting monthly over the following 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for new hires.
Astria Therapeutics (NASDAQ:ATXS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company initiated the ALPHA-ORBIT Phase 3 trial of navenibart for hereditary angioedema (HAE) in February 2025, with top-line results expected in early 2027.
Key financial metrics for 2024 include:
- Cash position of $328.1 million as of December 31, 2024
- Net loss of $94.3 million for full year 2024
- R&D expenses increased to $77.1 million
- G&A expenses rose to $34.5 million
The company expects its current cash position to fund operations into mid-2027. Phase 1b/2 ALPHA-STAR trial results showed 90-95% reduction in mean monthly attack rates. Additionally, Astria initiated a Phase 1a trial of STAR-0310 for atopic dermatitis, with initial results anticipated in Q3 2025.
Astria Therapeutics (ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted stock options to five new employees under its 2022 Inducement Stock Incentive Plan. The options cover 87,450 shares of common stock with an exercise price of $6.10, matching the closing price on March 3, 2025.
The options will vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly over the following 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement for new hires.
Astria Therapeutics (NASDAQ: ATXS) has initiated the ALPHA-ORBIT Phase 3 pivotal trial of navenibart for hereditary angioedema (HAE). The global, randomized, double-blind, placebo-controlled study will evaluate the drug's efficacy and safety over 6 months in up to 135 adults and 10 adolescents with HAE Type 1 or 2.
The trial features three dosing arms for adults: 600mg followed by 300mg every 3 months (Q3M), 600mg every 6 months (Q6M), and 600mg Q3M, plus placebo. Adolescents will receive 600mg followed by 300mg Q3M. The primary endpoint is time-normalized monthly HAE attacks at 6 months.
The Phase 3 program design was based on positive Phase 1b/2 ALPHA-STAR trial results, which demonstrated 90-95% reduction in mean monthly attack rate and up to 67% attack-free rate over 6 months. Top-line results are expected in early 2027.
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, announced that CEO Jill C. Milne, Ph.D. will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference.
The presentation is scheduled for Tuesday, March 4th at 9:50am ET in Boston, MA. Interested parties can access a webcast of the presentation through a provided link, and an archived replay will remain available in the investors section of the company's website for 30 days following the event.
This conference appearance represents an opportunity for Astria to share updates on their development of life-changing therapies with healthcare industry stakeholders and potential investors.
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company, announced its participation in the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025.
Three posters will be presented:
- Markus Magerl, M.D., from Charité Universitätsmedizin Berlin, will present the design of the global Phase 3 trial of navenibart (poster 617) titled, “ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Adolescent and Adult Participants with Type 1 and Type 2 Hereditary Angioedema (HAE).”
- Joshua S. Jacobs, M.D., from Allergy and Asthma Clinical Research, Inc., will present attack severity reduction data from the ALPHA-STAR Phase 1b/2 trial of navenibart (poster 606) titled, “Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial.”
- Chunxia Lily Zhao, Ph.D., from Astria Therapeutics, will present information on the profile of STAR-0310 (poster 697) titled, “Preclinical Data Supporting the Differentiated Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody.”
All presentations will occur in a poster session titled “Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema” starting at 9:45am PST on March 2, 2025, in the Convention Center, Ground Level, Hall A.
Astria Therapeutics (ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The options allow purchase of 16,500 shares at an exercise price of $7.43 per share, matching the closing price on February 3, 2025.
The options will vest over four years, with 25% vesting after the first year of employment and the remaining shares vesting monthly over the following 36 months. These grants comply with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees.
Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company specializing in allergic and immunologic disease therapies, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's CEO, Dr. Jill C. Milne, will engage in a fireside chat on Tuesday, February 11th at 10:40am ET.
The presentation will be accessible via webcast, with a replay available on the company's investor website for 30 days following the event. This virtual conference appearance represents an opportunity for Astria to showcase its developments in life-changing therapies to the investment community.
Astria Therapeutics (NASDAQ:ATXS) has announced its upcoming presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Scientific Session in Waimea, Hawaii, scheduled for February 9-13, 2025.
The presentation will focus on quality of life results from the Phase 1b/2 trial of navenibart (STAR-0215). Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at UC San Diego, will present an encore poster titled 'Navenibart (STAR-0215) Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial.'
The poster will be on display from 3:00pm ET on February 9 through February 13, 2025.
Astria Therapeutics (NASDAQ:ATXS) has initiated a Phase 1a clinical trial of STAR-0310, a high affinity monoclonal antibody OX40 antagonist for treating atopic dermatitis (AD). The trial will evaluate safety, tolerability, pharmacokinetics, and immunogenicity in approximately 40 healthy adult participants.
The randomized, double-blind, placebo-controlled single ascending dose trial is expected to provide early proof-of-concept results in Q3 2025. Preclinical results show STAR-0310 has significantly less antibody-dependent cellular cytotoxicity compared to rocatinlimab, a competing OX40 antagonist in Phase 3 development. STAR-0310 demonstrates a longer mean half-life of 26 days in cynomolgus monkeys versus 10-14 days for typical non-half-life extended IgG1 antibodies, while maintaining comparable potency to rocatinlimab.
